Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Forest Laboratories and Nycomed ‘to collaborate’

Forest Laboratories and Nycomed ‘to collaborate’

11th August 2009

Forest Laboratories and Nycomed have signed an agreement that will see the two pharmaceutical firms work together on the production and distribution of Daxas (roflumilast).

Under the agreement, Forest will pay Nycomed $100 million (60.7 million pounds) as well as future undisclosed sums as it takes responsibility for regulatory approval and commercialisation of Daxas.

“We have received considerable interest in the marketing rights to Daxas and we believe Forest Laboratories is the best possible partner for Nycomed”, explained Hakan Bjorklund, chief executive of Nycomed.

Nycomed developed Daxas for the treatment of chronic obstructive pulmonary disease and submitted its new drug application to the Food and Drug Administration in July.

The drug is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor.

These developments come after Forest Laboratories announced that its earnings per share value during the first quarter of 2009 stood at 87 cents – a rise on the 79 cents reported during the same time in 2008.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.